Intellia Therapeutics, Inc.·4

Jan 3, 4:30 PM ET

Lebwohl David 4

4 · Intellia Therapeutics, Inc. · Filed Jan 3, 2025

Insider Transaction Report

Form 4
Period: 2025-01-01
Lebwohl David
EVP, Chief Medical Officer
Transactions
  • Exercise/Conversion

    Restricted Stock Unit

    2025-01-013,1890 total
    From: 2025-01-01Exp: 2031-03-02Common Stock (3,189 underlying)
  • Exercise/Conversion

    Common Stock

    2025-01-01+3,18997,223 total
Footnotes (3)
  • [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
  • [F2]Includes 405 and 556 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2024 and December 31, 2024, respectively.
  • [F3]On March 3, 2021, the reporting person was granted 12,750 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.

Documents

2 files